...
首页> 外文期刊>Journal of Medicinal Chemistry >Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library
【24h】

Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library

机译:通过片段库的虚拟筛选发现的醛基酮还原酶AKR1C1和AKR1C3的选择性抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

Human aldo-keto reductases 1C1-1C4 (AKR1C1-AKR1C4) function in vivo as 3-keto-, 17-keto-, and 20-ketosteroid reductases and regulate the activity of androgens, estrogens, and progesterone and the occupancy and transactivation of their corresponding receptors. Aberrant expression and action of AKR1C enzymes can lead to different pathophysiological conditions. AKR1C enzymes thus represent important targets for development of new drugs. We performed a virtual high-throughput screen of a fragment library that was followed by biochemical evaluation on AKR1C1-AKR1C4 enzymes. Twenty-four structurally diverse compounds were discovered with low μM K _i values for AKR1C1, AKR1C3, or both. Two structural series included the salicylates and the N-phenylanthranilic acids, and additionally a series of inhibitors with completely novel scaffolds was discovered. Two of the best selective AKR1C3 inhibitors had K _i values of 0.1 and 2.7 μM, exceeding expected activity for fragments. The compounds identified represent an excellent starting point for further hit-to-lead development.
机译:人醛基酮还原酶1C1-1C4(AKR1C1-AKR1C4)在体内起3-酮,17-酮和20-酮类固醇还原酶的作用,并调节雄激素,雌激素和孕酮的活性及其占用和反式激活相应的受体。 AKR1C酶的异常表达和作用可导致不同的病理生理状况。因此,AKR1C酶代表了新药开发的重要目标。我们对片段库进行了虚拟高通量筛选,然后对AKR1C1-AKR1C4酶进行了生化评估。发现了二十四个结构不同的化合物,它们的AKR1C1,AKR1C3或两者的μMK _i值均低。两个结构系列包括水杨酸酯和N-苯基邻氨基苯甲酸,另外还发现了一系列具有全新骨架的抑制剂。两种最佳选择性AKR1C3抑制剂的K _i值为0.1和2.7μM,超过了片段的预期活性。鉴定出的化合物代表了进一步发展领先优势的良好起点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号